Foresight Diagnostics and Roche have entered into a licensing agreement covering the former’s PhasED-Seq technology for non-Hodgkin’s lymphoma (NHL).
Last year, Roche filed a lawsuit against Stanford University and Foresight in a US court. The Swiss healthcare company claimed that Foresight improperly utilised its genetic-sequencing trade secrets to create competing cancer-detection products.
The latest licensing agreement resolves legal disputes between the parties, dismissing all claims against Foresight, its founders, and Stanford University.
Under the terms of the deal, Foresight will grant Roche a non-exclusive sublicense for using PhasED-Seq under certain patents.
Roche will use the technology for the development of in vitro diagnostic kits for NHL.
Foresight holds an exclusive license for PhasED-Seq patents, while Stanford University holds the intellectual property rights.
The agreement allows Roche to incorporate PhasED-Seq into diagnostics for NHL, with royalty obligations to Foresight.
The collaboration is expected to help improve diagnostics in the field of haematological malignancies, advancing precision medicine initiatives.
Foresight CEO Jake Chabon said: “We are pleased to have resolved our differences with Roche and to move forward with this licensing agreement, which provides Roche with tailored rights in the field of non-Hodgkin’s lymphoma.
“This resolution allows Foresight to remain focused on our mission to advance cutting-edge diagnostics aimed at improving outcomes for cancer patients worldwide.”
In May 2025, Foresight forged a partnership with Germany-based molecular diagnostics provider Qiagen to develop and commercialise a kit-based version of its CLARITY assay.
Foresight CLARITY is a liquid biopsy platform that assesses minimal residual disease (MRD), providing critical insights for personalised treatment strategies.
The collaboration with Qiagen aims to develop a standardised in vitro diagnostic and companion diagnostic application for lymphoma and other blood cancers.
The regulated diagnostic kit will combine Foresight’s MRD detection technology with Qiagen’s molecular diagnostic expertise.
